The chemotherapy currently available for leishmaniasis relies on the administration of antimonial compounds; their toxicity and the emergence and spread of drug resistance emphasize the urgent need for affordable alternative drugs (3, 5) . The most significant advance has been the introduction of the first effective oral treatment with miltefosine, an alkyl-lysophospholipid (ALP), for the treatment of visceral leishmaniasis (16).
Glibenclamide, an inhibitor of K + ATP channels (2) and Pgp-glycoprotein (7), has been reported to inhibit uptake and multiplication of Leishmania within macrophages in vitro (13). The effect was associated with increased responsiveness to -interferon and to stimulation of Th1 mechanisms in general (13, 14) . In the present study we evaluate the glibenclamide was compared to the effect of 100 mg/kg/day glucantime. Although both drugs inhibited lesion enlargement in mice infected with the Gb S strain (Fig 2A) , the highest dose (80 mg/kg/day) proved more effective than glucantime (100 mg/kg/day) in reducing lesion size. In contrast, mice infected with amastigotes of the Gb 50R strain failed to respond to treatment with either glibenclamide or glucantime at the same concentrations used for Gb S (Fig. 2B) ; such unresponsiveness to glibenclamide confirmed the genetic stability of the resistant phenotype of Gb 50R , and the lack of an effect of glucantime on the course of the infection with Gb 50R suggests the occurrence of cross resistance to both drugs. After 49 days of treatment with either drug alone, mice
were treated with both drugs in combination for 20 more days. Lesion development in mice infected with Gb S diminished but did not stop when treated with either drug for 49 days, ceased completely when drug combination was used for 20 days, and recovered when the treatment was stopped ( 
